| 8.33 0.16 (1.96%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.35  |
1-year : | 11.98 |
| Resists | First : | 8.86 |
Second : | 10.26 |
| Pivot price | 8.01 |
|||
| Supports | First : | 6.61 | Second : | 5.5 |
| MAs | MA(5) : | 8.05 |
MA(20) : | 8.34 |
| MA(100) : | 11.86 |
MA(250) : | 10.18 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 51.2 |
D(3) : | 46 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 17.39 | Low : | 4.86 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KZIA ] has closed below upper band by 36.1%. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.38 - 8.42 | 8.42 - 8.45 |
| Low: | 8.02 - 8.05 | 8.05 - 8.09 |
| Close: | 8.27 - 8.33 | 8.33 - 8.4 |
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Wed, 21 Oct 2026
Guggenheim initiates Kazia Therapeutics stock with buy rating - Investing.com
Tue, 20 Oct 2026
Leerink initiates Kazia Therapeutics stock with $30 target - Investing.com
Tue, 22 Sep 2026
Kazia receives $2m milestone as paxalisib epilepsy trial starts - Investing.com
Tue, 01 Sep 2026
BTIG raises Kazia Therapeutics stock price target on trial data - Investing.com
Thu, 24 Apr 2025
Kazia Therapeutics (KZIA) Stock Price, News & Analysis - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 9.39e+006 (%) |
| Held by Institutions | 15.4 (%) |
| Shares Short | 906 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.784e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 641 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 1.9e+006 % |
| Gross Profit (p.s.) | 137.62 |
| Sales Per Share | -47.1 |
| EBITDA (p.s.) | 837004 |
| Qtrly Earnings Growth | -6.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 1 |
| Price to Book value | 0 |
| Price to Sales | -0.18 |
| Price to Cash Flow | 6.56 |
| Dividend | 0 |
| Forward Dividend | 1.17e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|